• About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact

Ellume enlists Bosch Australia to automate manufacturing for high-performance COVID-19 Test

Highlights

  • Ellume will collaborate with Bosch to create state-of-the-art automated production lines, to scale up manufacturing volumes of COVID-19 and other diagnostic tests.
  • Bosch capabilities will build resilience and innovation into the local Ellume manufacturing processes.
  • Bosch global automation and manufacturing know-how harnessed to ensure successful industrialisation of Ellume COVID-19 consumable test.
  • New Ellume manufacturing facility will be one of the biggest of its kind in the Southern Hemisphere.

Brisbane, Australia – 22 October 2020

Bosch Australia’s Manufacturing Solutions Division (BAMS), a leading supplier of factory automation for the medical device industry, announced today that digital diagnostics company, Ellume, would introduce BAMS technology to automate the high volume production of its COVID-19 diagnostic tests.

Brisbane based Ellume has developed a suite of COVID-19 tests for use by laboratories, doctors and consumers that gives results in less than 15 minutes. The Ellume technology was developed to address the unprecedented global demand for rapid, accurate diagnostics. The first batch of product has already been shipped to the United States and Ellume’s new manufacturing facility Richlands, Brisbane, is rapidly scaling-up its production capacity.

With extensive experience in precision assembly and production automation, BAMS will work closely with Ellume’s Engineering Team to build and install state-of-the-art automated assembly lines to increase production capacity. The assembly lines will include end of line functional testing to ensure reliable product quality.

“We are delighted to bring the BAMS automation expertise to support Australian med-tech manufacturing for a global market – a real positive for local manufacturing, and a positive for the testing and medical diagnosis of COVID-19”, said Gavin Smith, President of Bosch Australia.

Ellume CEO and founder Dr Sean Parsons said, “We’ve spent the last decade perfecting our technology, and now, in the midst of the COVID-19 pandemic, the role of rapid, accurate diagnostics has never been more important. Ellume is pleased to be working with Bosch to bring their world-leading automation know-how to our manufacturing process. This will allow Ellume to manufacture best-in-class diagnostics that can be relied on in a health crisis.”

With deep experience in factory automation solutions, and a growing portfolio of med-tech clients, BAMS has the ability to create robust and resilient manufacturing processes for Ellume.


ENDS

Ellume Media Contact
Patrick Condren
Media Relations
M: +61 405 186 630

Recent Posts
  • QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test
  • Push to allow at-home COVID tests in Australia
  • Why Aussie startup Ellume’s home-testing tech should help us in the COVID-19 recovery, but can’t
  • An Australian firm producing home COVID-19 tests for the US market has called on the federal government to reconsider its ban
  • Rapid COVID-19 Testing Device, Sunrise Interview with Ellume CEO Dr Sean Parsons
Archives
Categories
Business

10 News First reports Ellume’s $42M NIH funding for rapid COVID test

Previous thumb

ABC Radio “The Money” Interview with Ellume CEO, Dr Sean Parsons

Next thumb
Scroll
ellume logo white
Menu

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
News

Quick Links

Contact Us
Terms of Use
Privacy Policy
Whistleblower Policy

Some Ellume products are pending regulatory clearance. © Ellume Limited 2021
ABN 13 141 767 660